Molecular response in acute promyelocytic leukemia: A direct comparison of regular and real-time RT-PCR

Leukemia

Volumn 20, Issue 8, 2006, Pages 1393-1399

  Liu, Y F ^a   Zhu, Y M ^a   Shen, S H ^a   Shen, Z X ^a   Li, J M ^a   Chen, S J ^a   Chen, Z ^a   Jiong, H U ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute promyelocytic leukemia; Molecular response; PML RAR ; Real time RT PCR

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HOMOHARRINGTONINE; METHOTREXATE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MEDICAL DOCUMENTATION; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 33746173336     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404262     Document Type: Article

References (39)

1. Avvisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol 2001; 38: 4-12.
2. Huang ME, Ye YC, Chen SR, Chai JR, Zhoa L, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
3. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
4. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
5. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
6. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
7. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-1052.
8. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269.
9. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335.
10. Castaigne S, Balitrand N, de The H, Dejean A, Degos L, Chomienne C. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110-3115.
11. 3: An experience of 120 patients at a single institution. Int J Hematol 1999; 70: 248-260.
12. Gameiro P, Vieira S, Carrara P, Silva AL, Diamond J, Botelho de Sousa A et al. The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients. Haematological 2001; 86: 577-585.
13. Martinelli G, Remiddi C, Visani G, Farabegoli P, Testoni N, Zaccaria A et al. Molecular analysis of PML-RAR alpha fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients. Br J Haematol 1995; 90: 966-968.
14. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. GIMEMA-AIEOP Multi-center 'AIDA' Trial. Blood 1998; 92: 784-789.
15. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncooga Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
16. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
17. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: A model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-1973.
18. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-328.
19. Gu BW, Hu J, Xu L, Yan H, Jin WR, Zhu YM et al. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia. Hematol J 2001; 2: 330-340.
20. Gallagher RE, Yeap BY, Livak KJ, Beaubier N, Bloomfield CD, Appelbaum FR et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
21. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS et al. Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993; 82: 1264-1269.
22. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Koheseisho). Blood 1999; 93: 3074-3080.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient, II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
25. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial. Blood 1999; 93: 4131-4143.
26. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell Jr RP, Miller Jr WH. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651-2656.
27. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61-66.
28. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
29. Jurcic JG. Monitoring PML-RARalpha in acute promyelocytic leukemia. Curr Oncol Rep 2003; 5: 391-398.
30. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 7: 2318-2357.
31. Chen SJ, Chen Z, Chen A, Tong JH, Dong S, Wang ZY et al. Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 1992; 7: 1223-1232.
32. Paietta E, Goloubeva O, Neuberg D, Bennett JM, Gallagher R, Racevskis J, et al., Eastern Cooperative Oncology Group. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom 2004; 59: 1-9.
33. Vahdat L, Maslak P, Miller Jr WH, Eardley A, Heller G, Scheinberg DA et al. Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PML/RARα isoform, and CD13 expression in patients treated with all-trans retinoid acid. Blood 1994; 84: 3843-3849.
34. Gallagher R, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D et al. Association of PML/RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 1997; 90: 1656-1663.
35. Kiyoi H, Naoe T. FLT3 in human hematologic malignancies. Leuk Lymphoma 2002; 43: 1541-1547.
36. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901-1908.
37. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189.
38. Chillon MC, Fernandez C, Garcia-Sanz R, Balanzategui A, Ramos F, Fernandez-Calvo J et al. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. Hematol J 2004; 5: 239-246.
39. Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ES et al. FLT-3 aberrations in acute promyelocytic leukaemia: Clinicopathological associations and prognostic impact. Br J Haematol 2004; 125: 463-469.